



prescient
therapeutics

15 October 2015

The Company Announcements Platform
ASX Limited
By E-lodgement

Prescient Announces Executive Management Change

Melbourne, Australia, 15 October 2015: Prescient Therapeutics Limited (ASX:PTX), a clinical stage oncology company, advises that Dr Robert Crombie has resigned from his position as Managing Director. The company has initiated a search for his replacement. Mr Paul Hopper will lead the company in his ongoing executive director role until a replacement is appointed. Dr Crombie intends to focus on other business opportunities.

“The Board is appreciative to Rob for his contributions in initiating the clinical programs and building the management team during the first 18 months of the company’s life,” said Chairman Steven Engle. “We also appreciate Paul stepping into the leadership role on an interim basis.”

Mr Hopper said, “From a clinical perspective, Prescient is in an enviable position. The company recently reported encouraging early clinical data from its Phase 1b/2 Investigator Sponsored Trial of PTX-200 in patients with breast, lung and oesophageal cancer. We expect strong news flow and progress across several cancer drug targets over the next year. As we continue to execute on our programs, we will seek a permanent CEO who is ready to take Prescient to the next level.”

Ends.

About Prescient Therapeutics

Prescient Therapeutics is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida’s Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, Prescient is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia in 2015.

Prescient’s second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors. Prescient expects to commence Phase 1b/2 clinical trials in breast cancer and multiple myeloma in 2015. At the same time, Prescient plans to develop its novel p27 cancer biomarker as a companion diagnostic that will potentially identify those patients that are most likely to respond to PTX-100 therapy.

Prescient has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.

Further Inquiries:

Steven Engle

Chairman

+1 858 922 7768

Rudi Michelson

Monsoon Communications

+61 (0) 3 9620 3333